Literature DB >> 6424399

Hepatic toxicity of antiepileptic drugs: a review.

L Gram, K D Bentsen.   

Abstract

Hepatic toxicity of antiepileptic drugs has been well recognized for many years. Despite the increasing awareness of chronic toxicity of antiepileptic drugs, this aspect has remained of limited importance. Since the introduction of valproate, this situation has changed fundamentally. Following a general introduction to the classification and symptomatology of drug-induced hepatic toxicity, a detailed description of hepatic toxicity caused by phenytoin, carbamazepine, and valproate is presented, including classification, symptomatology and histological features. Hepatic toxicity caused by all three drugs may be classified as idiosyncratic reactions. However, whereas toxic reactions following phenytoin and carbamazepine are characterised by a rather short duration of exposure before symptoms occur with accompanying clinical features of hypersensitivity, valproate-induced hepatic toxicity exhibits no signs of hypersensitivity and often occurs following prolonged exposure, speaking in favor of a metabolic aberration as the underlying cause. Hypotheses explaining the mechanisms involved in this phenomenon are reviewed. Guidelines for averting valproate-induced hepatic toxicity are presented.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6424399     DOI: 10.1111/j.1600-0404.1983.tb01537.x

Source DB:  PubMed          Journal:  Acta Neurol Scand Suppl        ISSN: 0065-1427


  8 in total

1.  The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase.

Authors:  H G Aldenhövel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

Review 2.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

Review 3.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  The risk-benefit ratio of anticonvulsant drugs.

Authors:  M J Eadie
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 5.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 6.  Drug-induced hepatic disorders. Incidence, management and avoidance.

Authors:  M Døssing; J Sonne
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

7.  Epileptic seizure disorders. Developments in diagnosis and therapy.

Authors:  E Niedermeyer; W Froescher; R S Fisher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

8.  Beverage-induced enhanced bioavailability of carbamazepine and its consequent effect on antiepileptic activity and toxicity.

Authors:  Sanmoy Karmakar; Sreerupa Biswas; Rammohan Bera; Samiran Mondal; Amit Kundu; Md Asif Ali; Tuhinadri Sen
Journal:  J Food Drug Anal       Date:  2014-12-03       Impact factor: 6.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.